Kerry Ann Stewart MITCHELL

Dr. Kerry Ann Stewart MITCHELL

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in The Lancet
Verified
Journal Article
Closed access
RGReinou S Groen
Reinou S Groen
MSMohamed Samai
Mohamed Samai
KMKerry Ann Stewart MITCHELL
Kerry Ann Stewart MITCHELL
LCLaura D Cassidy
Laura D Cassidy
TKThaim B Kamara
Thaim B Kamara
AKAdam L Kushner
Adam L Kushner

1 December 2010 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
KMKerry Ann Stewart MITCHELL
Kerry Ann Stewart MITCHELL
KWKaren S. Wilcox
Karen S. Wilcox
RFRobert S. Fujinami
Robert S. Fujinami
HWH. Steve White
H. Steve White
Viral infection of the central nervous system can lead to long-term neurologic defects, including increased risk for the development of epilepsy. We

28 January 2011 in Epilepsia
Verified
Journal Article
Open access
PDF file
PTPanos Theofilas
Panos Theofilas
SBSukhmani Brar
Sukhmani Brar
KMKerry Ann Stewart MITCHELL
Kerry Ann Stewart MITCHELL
Hai-Ying ShenHai-Ying Shen
Hai-Ying Shen
USUrsula S. Sandau
Ursula S. Sandau
DBDetlev Boison
Detlev Boison
Purpose: Given the high incidence of refractory epilepsy, novel therapeutic approaches and concepts are urgently needed. To date, viral‐mediated delivery and endogenous expression of antisense sequences as a strategy to prevent seizures have received little attention in epilepsy therapy development efforts. Here we validate adenosine kinase (ADK), the astrocyte‐based key negative regulator of the brain’s endogenous anticonvulsant adenosine, as a potential therapeutic target for antisense‐mediated seizure suppression. Methods: We developed adenoassociated virus 8 (AAV8)‐based gene therapy vectors to selectively modulate ADK expression in astrocytes. Cell type selectivity was achieved by expressing an Adk‐cDNA in sense or antisense orientation under the control of an astrocyte‐specific gfaABC1D promoter. Viral vectors where injected into the CA3 of wild‐type mice or spontaneously epileptic Adk‐tg transgenic mice that overexpress ADK in brain. After virus injection, ADK expression was assessed histologically and biochemically. In addition, intracranial electroencephalography (EEG) recordings were obtained. Key Findings: We demonstrate in wild‐type mice that viral overexpression of ADK within astrocytes is sufficient to trigger spontaneous recurrent seizures in the absence of any other epileptogenic event, whereas ADK downregulation via AAV8‐mediated RNA interference almost completely abolished spontaneous recurrent seizures in Adk‐tg mice. Significance: Our data demonstrate that modulation of astrocytic ADK expression can trigger or prevent seizures, respectively. This is the first study to use an antisense approach to validate ADK as a rational therapeutic target for the treatment of epilepsy and suggests that gene therapies based on the knock down of ADK might be a feasible approach to control seizures in refractory epilepsy.

5 August 2010 in Epilepsia
Verified
Journal Article
Closed access
PDF file
KMKerry Ann Stewart MITCHELL
Kerry Ann Stewart MITCHELL
KWKaren S. Wilcox
Karen S. Wilcox
RFRobert S. Fujinami
Robert S. Fujinami
HWH. Steve White
H. Steve White

1 April 2019 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
AFArtur Fahradyan
Artur Fahradyan
MTMichaela Tsuha
Michaela Tsuha
EWErik M. Wolfswinkel
Erik M. Wolfswinkel
KMKerry Ann Stewart MITCHELL
Kerry Ann Stewart MITCHELL
JHJeffrey A. Hammoudeh
Jeffrey A. Hammoudeh
WMWilliam Magee
William Magee

1 May 2013 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
KMKerry Ann Stewart MITCHELL
Kerry Ann Stewart MITCHELL
RGReinou S. Groen
Reinou S. Groen
TKThaim B. Kamara
Thaim B. Kamara
MFMina M. Farahzad
Mina M. Farahzad
MSMohamed Samai
Mohamed Samai
SWSherry M. Wren
Sherry M. Wren
Traumatic injuries account for a significant proportion of the global burden of disease, causing 9% of all deaths worldwide.1 More than 90% of injury-related deaths occur in low- and middle-income countries.1 Despite the overall impact, the burden and pattern of injuries in developing countries are not well known, and there have been a limited number of studies addressing this issue.2-4 Most of the available data are extrapolated from hospital-based studies, which inherently have limited generalizability since many patients with injuries will not or cannot go to a hospital because of various factors such as availability, cost, transportation, and trained staff.5,6 Thus, the use of hospitalization data, particularly in nations where surgical care is sparsely available, will exclude a significant proportion of patients with injuries and underestimate the incidence, prevalence, and morbidity of traumatic injuries.7 This is in contrast to the majority of trauma literature, which primarily encompasses higher-income countries with established systems to track nationwide trauma care. Similar efforts to study injury in low-income countries, particularly in Sub-Saharan Africa, have been near impossible because of lack of resources; as such, an accurate nationwide characterization of trauma in developing countries does not exist at this time. The vast underrepresentation of the global burden of traumatic injury in the trauma literature likely impacts public health policies and resource allocations.8